I-Hyaluronate evunyelwe isetshenziswe ku-Viscosupplementation
I-Supartz, isisombululo se-sodium hyaluronate, ingenye yama-hyaluronates asetshenziselwa i- viscosupplementation . I-Supartz ifakwe ngqo emadolweni ekuhlanganyeleni ukubuyisela izindawo zokugcoba nokugcoba kwe-synovial fluid (okungukuthi, i-joint fluid). I-hyaluronate ye-sodium esetshenziselwa i-Supartz ikhishwa ezinkomeni zenkukhu. I-hyaluronate ye-sodium iyi-polysaccharide equkethe ama-disaccharide units of glucuronic acid no- N-acetylglucosamine .
Ukuvunyelwa kuka-Supartz no-Supartz Fx
I-Supartz yamukelwa yi-US FDA ngoJanuwari 24, 2001 yokwelapha i-knee osteoarthritis ezigulini ezihluleka ukuthola ukutholakala okwanele ngemithi yokwelashwa, okubandakanya ukuvivinya umzimba, ukwelashwa ngokomzimba, imithi yokwelashwa , izinsiza zokuhamba , namaphakethe ashisayo noma abandayo . Ukusetshenziswa kwamanye amalunga kuyaphenywa. I-Supartz yasetshenziswa eJapane kusukela ngo-1987. Ijojowe kanye ngesonto ngomjikelezo weviki 5. Ezinye iziguli zingase zithole impendulo emihle emva kwamasonto amathathu.
Ngo-Okthoba 12, 2015, uBooventus, umenzi we-Supartz, umemezele ukuqaliswa kwe-Supartz Fx (10 mg ye-hyaluronate ye-sodium ehlakazekile ngo-1.0% we-saline yezinto eziphilayo), ene-label eyandisiwe kusukela ku-Supartz yasekuqaleni, okuvumela ukujikeleza kokujova. Ngenkathi ilebula lokuphepha likhuliswa ukwenzela umjikelezo womjovo wokuphindaphindiwe, ukuphumelela kwemijikelezo ephindaphindiwe kungakaqali.
Ukuxwayiswa nokuqapha
I-Supartz akufanele ihanjiswe kunoma yisiphi isineke nge-hypersensitivity eyaziwayo emikhiqizo ye-sodium hyaluronate.
Ukuqapha kufanele kusetshenziswe lapho ukwelapha iziguli ezinezifo eziphuthumayo ezinamaprotheni, amaqanda, noma amaphiko. Iziguli ezine-infection noma izifo zesikhumba endaweni lapho umjovo onganikezwa khona akufanele ziphathwe nge-Supartz.
Ukuphepha nokusebenza kweSupartz akuzange kusungulwe kwabesifazane abakhulelwe, noma kwabesifazane abalahlayo.
Ukusetshenziswa kwalo akukafundwanga ezinganeni.
Imiphumela Ejwayelekile Ejwayelekile
Imiphumela emibi evamile noma izenzakalo ezimbi ezihlobene ne-Supartz zihlanganisa:
- Ubuhlungu obuhlangene ngaphandle kokuvuvukala
- Ukuhlungu obusemhlane
- Ubuhlungu obungavamile
- Ukusabela kwesayithi lokungena
- Ikhanda
Ukuvuvukala noma ubuhlungu, okuyinto ehamba isikhathi eside, kungenzeka kuhlangene obekwe nge-Supartz. Iziguli zelulekwa ukuba zigweme imisebenzi eqinile noma isisindo emahoreni angu-48 kulandela umjovo.
Okubalulekile
Ukuhlaziywa kwezilingo ezinhlanu zokwelashwa okwenzelwe kahle akudalanga umehluko omkhulu phakathi kweSupartz namaqembu okulawula ngokwezenzakalo ezimbi. Ngenkathi ukuphepha kukaSupartz nezinye izinhlayiya ze-viscosupplements kuye kwaphakanyiswa izifundo zokwelashwa, kuqhutshwe ngempumelelo ukuphumelela. Ngokuqondene nokusebenza kahle, ukubuyekezwa kweCochrane kwaphetha ngokuthi i-viscosupplementation iphumelela kakhulu kune-placebo, kodwa kwakukhona nezinye izifundo ezafinyeleka ekuqinisekiseni ukuthi ukujola kuhlinzeka ukukhululeka okukhulu kobuhlungu.
Imithombo:
I-Supartz Fx. Ukubeka imininingwane. I-Bioventus. http://www.supartzfx.com/wp-content/uploads/2015/07/SUPARTZ_FX_Package_Insert.pdf
I-Bioventus Ivula i-Supartz Fx Manje Nge-Label Ekhulisiwe Yokuphepha Yokuphindaphinda Imijikelezo Yokungenwa E-Knee Osteoarthritis. Okthoba 12, 2015.
http://www.bioventusglobal.com/news/press-releases/bioventus-launches-supartz-fx%E2%84%A2-now-expanded-safety-label-repeat-injection-cycles
I-Hyaluronic acid (i-Supartz): ukubuyekezwa kokusetshenziswa kwayo ku-osteoarthritis yamadolo. I-Curan MP. Izidakamizwa nokuguga. Novemba 2010.
http://www.ncbi.nlm.nih.gov/pubmed/20964466